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ferent atrophy patterns in PCA patients compared with typical amnestic Alzheimer’s disease (tAD)
patients, with greatest atrophy commonly found in posterior regions in the PCA group, whereas in the
tAD group, atrophy is most prominent in medial temporal lobe regions. However, differential longi-
tudinal atrophy patterns are not well understood.
Methods: This study assessed longitudinal changes in brain and gray matter volumes in 17 PCA pa-
tients, 16 tAD patients, and 18 healthy control subjects. Both patient groups had symptom durations
of approximately 5 years.
Results: Progressive gray matter losses in both PCA and tAD patients were relatively widespread
throughout the cortex, compared with control subjects, andwere not confined to areas related to initial
symptomatology. A multivariate classification analysis revealed a statistically significant group sep-
aration between PCA and tAD patients, with 72.7% accuracy (P , .01).
Conclusion: Progression from an initially focal presentation to a more global pattern suggests that
these different clinical presentations of AD might converge pathologically over time.
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Alzheimer’s disease (AD) is the most common cause of
dementia in people aged .65 years [1], and it is estimated
to affect 81 million people worldwide by 2040 [2]. It is
typically characterized by an insidious onset of memory
impairment that progresses to involve multiple cognitive
domains [3]. This amnestic presentation is in accordance
with histopathological and structural imaging studies show-
ing early medial temporal lobe involvement. Intracellular
neurofibrillary tangles (a hallmark of AD) are first seen
in the transentorhinal cortex and then in the hippocampus
[4]. Neuroimaging evidence suggests atrophy of medialuthor. Tel.: 44 (0)8451 555 000 extension 723962;
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1.09.225temporal lobe structures is an early feature of typical am-
nestic Alzheimer’s disease (tAD) and predicts progression
to AD in individuals with mild cognitive impairment
(MCI) [5,6].
However, less typical forms of AD have been described in
which memory is not the primary deficit [7]. In particular,
posterior presentations of AD are increasingly recognized.
Individuals may present with visuospatial, visuoperceptual,
praxis, calculation, and spelling difficulties, which implicate
early parietal and occipital lobe involvement [8,9]. The
posterior pattern of atrophy with which these presentations
are associated has led to the term posterior cortical atrophy
(PCA). The underlying pathology in these patients is most
commonly AD, which is found concentrated in the occipital
and parietal lobes [10,11]. A smaller proportion of PCA
cases may be underpinned by other conditions such as
dementia with Lewy bodies, corticobasal degeneration, or,
rarely, Creutzfeldt–Jakob disease [12,13].eserved.
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ies have shown that PCA patients have greater parietal atro-
phy and less medial temporal and hippocampal atrophy
compared with tAD patients [14,15]. Longitudinal studies
investigating how this atrophy pattern changes over time
are lacking. In particular, longitudinal investigations are
needed to assess whether the focal patterns of atrophy
remain confined to these regions or whether they become
more global. The areas of greatest change may not be the
areas that are most atrophied initially. Results from
longitudinal studies of PCA may allow for a better
understanding of the natural history of both PCA and AD.
A number of techniques have been developed to study
longitudinal changes in specific structures and across the
whole brain. A widely used method to quantify changes
over time in whole brain volume is the boundary shift inte-
gral (BSI; [16]). This method has been applied to measure
whole brain atrophy in a range of neurological disorders, in-
cluding AD [17], frontotemporal lobar degeneration [18],
Huntington disease [19], and progressive supranuclear palsy
[20]. This measure is also used as an outcome measure in
clinical trials of therapies targeted at AD pathology
[21,22]. Another method that assesses local volumetric
changes over time across the whole brain uses nonlinear
(fluid) registration and estimates volume changes from the
deformation fields needed to match an individual’s serial
scans [23]. This method can be used in combination with
voxel-based morphometry (VBM) to assess local changes
in gray matter, white matter, and cerebrospinal fluid
(CSF), and has previously been applied to AD [24,25] and
frontotemporal lobar degeneration [26].
The aim of the current study was to assess longitudinal
changes in whole brain volume and gray matter volume in
PCA, and compare these with structural changes over time
in groups of tAD patients and healthy control subjects.Table 1
Subject demographics
Characteristics Control subjects
N 18
Sex, male/female 7/11
Age in years at baseline, mean (SD) 64.0 (5.0)
Interval between time points in months, mean (SD) 12.4 (0.6)
Disease duration in years at baseline, mean (SD) N/A
MMSE at baseline, mean (SD) 29.4 (0.7)yy
MMSE at follow-up, mean (SD) 29.3 (1.1)yy
TIV at baseline in mL, mean (SD) 1477.9 (131.9)
Whole brain volume at baseline in mL, mean (SD) 1118.7 (103.1)
Whole brain volume at follow-up in mL, mean (SD) 1120.3 (98.3)
Abbreviations: PCA, posterior cortical atrophy; tAD, typical amnestic Alzheim
volume.
*ANOVA (except sex).
yFisher exact test.
zCompared with control subjects.
xCompared with PCA patients.
{P , .001.
**P , .0001.
yyAvailable for 10 control subjects.Specifically, two possible outcomes were predicted: patterns
of atrophy progression are either (i) focal, with PCA patients
showing greater atrophy changes in posterior regions com-
pared with control subjects and tAD patients, and tAD show-
ing greater atrophy changes in medial temporal lobe regions
compared with control subjects and PCA patients, leading
to significantly different patterns of atrophy changes between
PCA and tAD patients, or (ii) global, with PCA and tAD pa-
tients showingwidespread changes of atrophy comparedwith
control subjects, and only subtle differences in the direct com-
parison of PCA and tAD patients. Understanding the progres-
sion of atrophy in PCA patients may improve diagnosis and
the quality of prognostic information given to these patients.2. Materials and methods
2.1. Subjects
The study included 17 PCA patients, 16 tAD patients, and
18 healthy control subjects. All subjects were identified ret-
rospectively from a clinical database. Demographics of the
subjects are summarized in Table 1. All clinically affected
subjects had attended the Specialist Cognitive Disorders
Clinic at the National Hospital for Neurology and Neurosur-
gery, London, United Kingdom. Informed consent was ob-
tained from all subjects, and the study had local ethics
committee approval. All PCA and tAD patients (100%)
and 12 control subjects (67%) had been included in a
previous cross-sectional imaging study [15]. All subjects
underwent comprehensive clinical and neuropsychological
assessment. The clinical notes of all PCA patients were re-
viewed by a clinician to identify initial symptoms and clin-
ical findings (Table 2). An overview of the proportion of
PCA and tAD patients showing impaired performance (be-
low the fifth percentile) on neuropsychological tests ofPCA patients tAD patients P value*
17 16 N/A
6/11 7/9 .9y
64.3 (4.7) 72.6 (7.1)zx{ ,.001
12.0 (1.1) 11.6 (0.9) .06
5.1 (2.4) 4.7 (3.1) .7
21.4 (5.2)z** 19.3 (3.8)z** ,.0001
18.8 (5.9)z** 16.9 (4.0)z** ,.0001
1466.7 (153.3) 1448.5 (140.1) .8
983.2 (121.4)z{ 965.4 (96.2)z{ ,.0001
966.1 (129.2)z{ 949.0 (98.2)z{ ,.0001
er’s disease; MMSE, Mini-Mental State Examination; TIV, total intracranial
Table 2
Frequency of first reported symptoms and clinical features on neurological
examination in the PCA group
Symptoms Percent deficits present
Initial symptoms
Calculation 71%
Memory 47%
Spelling 41%
Locating objects 41%
Reading 35%
Perceiving distances/depth 35%
Word-finding 35%
Writing 24%
Facial recognition 18%
Identifying objects 12%
Clinical features
Dyspraxia 47%
Visual disorientation 24%
Myoclonus 6%
Extrapyramidal signs 6%
M. Lehmann et al. / Alzheimer’s & Dementia 8 (2012) 502–512504memory, arithmetic, naming, spelling, speed (letter cancel-
lation), and visuospatial and visuoperceptual processing is
provided in Table 3.
2.1.1. Inclusion criteria
All patients had to have at least two MRI scans, approxi-
mately 1 year apart, on the same scanner to be included in the
study. Individuals were only included in the PCA group if
clinical assessment and investigation provided no indication
of a non-AD dementia (e.g., dementia with Lewy bodies,
corticobasal degeneration). All PCA patients fulfilled theTable 3
Proportion of PCA and tAD patients showing deficits on neuropsychological
tests
Cognitive deficits*
PCA tAD
Visit 1y Visit 2 Visit 1 Visit 2
Memory (verbal)1 29%z 47% 100% 100%
Memory (visual)1 – – 100% 94%
Visuospatial2 88%x 94% 44% 81%
Visuoperceptual3 82% 88% 81% 81%
Naming4 59% 71% 56% 81%
Arithmetic5 35%x 41% 81% 75%
Speed6 100%{ 100% 69% 63%
Spelling**7 50% 60% – –
*Proportion (%) of subjects performing below the fifth percentile.
yc2 test comparing baseline assessments between PCA and tAD patients.
zP  .001.
xP  .01.
{P  .05.
**Available in 10 PCA subjects.
1Short Recognition Memory Test [27] or Easy Recognition Memory Test
for words [28].
2VOSP Number location test [29].
3VOSP Object Decision or VOSP Silhouettes test [29].
4Graded Naming test, verbal version of this test in 10 PCA patients [30].
5Graded Difficulty Arithmetic test [31].
6Letter cancellation test [32].
7Graded Difficulty Spelling test [33].clinical criteria proposed by Mendez et al and Tang-Wai
et al [34,35]. In addition, patients had to fulfill a set of
behavioral criteria at some stage in their clinical history,
chosen to assess quantitatively the cognitive domains most
commonly affected in PCA patients. Patients had to
demonstrate deficits on at least two of four standardized
tests of parietal/occipitoparietal dysfunction. The Number
Location and Object Decision subtests from the Visual
Object and Space Perception battery were used to detect
visuospatial and visuoperceptual dysfunction, respectively,
skills commonly impaired after right or bilateral parietal
damage [29]. The Graded Difficulty Arithmetic and the
Graded Difficulty Spelling tests assess numeracy and literacy
functions, which are commonly compromised by left parietal
damage [31,33]. This decision of failing at least two of the
aforementioned posterior cortical function tests was made
to ensure that criteria are sensitive to parietal dysfunction,
while not being so specific as to exclude PCA patients with
either a relatively asymmetric or focal syndrome at onset.
In addition, patients had to demonstrate relatively preserved
episodic memory (below the fifth percentile on a short
Recognition Memory Test; [27]), to distinguish patients
with PCA from those with a more typical amnestic presenta-
tion of AD.
All tAD patients fulfilled National Institute of Neurologi-
cal and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association cri-
teria for probable AD, with recently proposed revisions
[3,36], and additionally demonstrated significant episodic
memory impairment (below the fifth percentile on verbal
and visual Recognition Memory Tests; [37]).2.2. MRI acquisition
All scans were acquired on the same scanner, and scan
acquisition was consistent between time points for each sub-
ject. T1-weighted volumetric MR scans were obtained on
a 1.5-T General Electric (Milwaukee, WI) Signa scanner
using an inversion recovery-prepared fast spoiled gradient
recalled sequence, with a 24-cm field of view and 256 !
256 matrix providing 124 contiguous 1.5-mm-thick slices
in the coronal plane. Scanning parameters were as follows:
repetition time 5 12 ms or 15 ms, echo time 5 5.4 ms,
and inversion time 5 650 ms.2.3. Registration of repeat to baseline image
Both baseline and repeat brain regions were delineated
using a semiautomated technique based on intensity thresh-
olding and mathematical morphological operations [38].
The delineated repeat brain images were then registered to
baseline images using 12-degree-of-freedom registration
[39,40]. Differential bias correction (DBC) was applied to
the registered baseline and repeat images using a kernel
radius of 5 voxels, to correct for differences in intensity
inhomogeneity artifacts between the two images [41].
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The registered and DBC-corrected scan pairs were used
to calculate volume changes using the BSI algorithm, as
described in Leung et al (KN-BSI; [42]).
2.5. Fluid registration
The registered and DBC-corrected scan pairs were
cropped using subject-specific masks to exclude nonbrain
regions (e.g., neck and eye), while including lateral ventric-
ular CSF, gray matter, white matter, and a layer of brain sur-
face CSF. The fluid registration [23] warps each individual’s
repeat image to match the corresponding baseline image
based on a physical model of a compressible viscous fluid.
Fluid registrations were run until a stopping criterion based
on the derivative of the cost function of the registration was
reached [43]. The fluid registration generates a detailed
deformation field for each subject. The amount of voxel-
level expansion or contraction was extracted from each de-
formation field by computing the Jacobian determinant at
each voxel (i.e., the determinant of the gradient of the defor-
mation field). The Jacobian determinants were then log-
transformed, and the resulting “voxel-compression map”
for each subject was stored.
2.6. Voxel-based morphometry
The voxel-compression maps as well as the baseline im-
ages were converted to Neuroimaging Informatics Technol-
ogy Initiative format (http://nifti.nimh.nih.gov) to process
them using SPM8 (Statistical Parametric Mapping [Well-
come Trust Centre for Neuroimaging, UCL, London, UK],
version 8, http://www.fil.ion.ucl.ac.uk/spm), executed in
MATLAB 7.2 (MathWorks, Sherborn, MA). The baseline
images were segmented into gray matter, white matter, and
CSF using SPM8’s new segment toolbox with default set-
tings. Segmentations were produced with rigid alignment
to standard space (the international consortium for brain
mapping template) and resampled to 1.5-mm isotropic vox-
els for use with Diffeomorphic Anatomical Registration
Through Exponentiated Lie algebra (DARTEL) [44]. DAR-
TEL then iteratively registered the gray matter segments to
an evolving estimate of their groupwise average [45]. The
transformation parameters required to warp the original seg-
ments to the final template (i.e., rigid alignment plus DAR-
TEL warping) were applied to the gray matter segments and
the voxel-compression map images to normalize them to the
groupwise average template. The warped gray matter seg-
ments were then thresholded at a value of 0.5 to produce
binary masks that were then used to multiply the voxel-
compression map images to generate separate gray matter
voxel-compression maps for each subject. These gray matter
voxel-compression maps were smoothed using an isotropic
Gaussian kernel of 6-mm full width at half maximum to ren-
der the data more normally distributed and to correct for mi-
nor misalignments after normalization.2.7. Statistical analysis
Differences in measures of atrophy between groups were
analyzed using a general linear model (GLM) with a three-
level group factor, adjusting for covariates, as specified in
later text.
2.7.1. Boundary shift integral
BSI measures were annualized and differences in rates of
atrophy between groups were analyzed using a GLM with
age and sex included as covariates.
2.7.2. Voxel-based morphometry
Longitudinal volume changes were analyzed using
a GLM, adjusting for age, sex, and interval between time
points. An explicit mask was applied to include only voxels
for which the intensity was at least 0.1 in at least 80% of the
images [46]. Statistical significance of the group differences
was tested using a multiple comparison correction to control
the false discovery rate (FDR; [47]) at P 5 .05. Results are
displayed as overlays on a study-specific template, which
was created by normalizing all original images using the
DARTEL transformations and calculating the average of
the warped brain images. Group differences are presented
either as statistical difference maps (FDR-corrected) or as
effect size maps (using Pearson correlation coefficients).2.8. Support vector machine
A linear support vector machine (SVM; [48]) was used to
assess how well patterns of gray matter volume derived from
the VBM analysis can separate the three groups (control sub-
jects, PCA patients, and tAD patients). The SVM analysis
was implemented with LIBSVM version 2.89 [49] under
MATLAB (version 7.2.0; MathWorks). SVMs identify an
optimal separating hyperplane in this space such that sub-
jects from each group lie as far as possible from the hyper-
plane, on opposite sides. After the hyperplane has been
defined, scores can be generated by projecting the points
onto the normal of the hyperplane; the direction of the nor-
mal can be visualized as an image, showing the relative
weights and signs of vertices’ contributions to the classifier
scores. We used the C-SVM formulation, which uses a two-
level nested cross-validation to optimize the misclassifica-
tion penalty parameter C using a leave-one-out procedure
within the main leave-one-out loop [50]. This ensures an un-
biased estimation of generalization accuracy by leaving each
scan in turn entirely out of the training procedure.3. Results
3.1. Subjects
As shown in Table 1, there was no evidence of a difference
in sex distribution or age between the PCA and control groups
(P. .8, both tests). However, the tAD group was older com-
pared with control and PCA groups (both P , .001). As
Table 4
Overview atrophy rates (BSI) in control subjects, PCA patients, and tAD
patients
BSI group characteristics
and comparisons
BSI, annualized,
in mL
BSI annualized, %
of whole brain
volume at baseline
Means and SD
Control subjects 4.0 (4.5) 0.3 (0.4)
PCA patients 22.3 (6.0) 2.3 (0.7)
tAD patients 18.1 (7.4) 1.9 (0.8)
Adjusted differences and
confidence intervals
Control subjects versus PCA
patients
18.4 (14.4, 22.3)* 2.0 (1.6, 2.4)*
Control subjects versus tAD
patients
16.8 (12.0, 21.6)* 1.8 (1.3, 2.3)*
PCA patients versus tAD
patients
1.6 (23.2, 6.4) 0.2 (20.3, 0.7)
P (across all groups) ,.0001 ,.0001
Abbreviation: BSI, boundary shift integral.
*P , .0001.
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follow-up Mini-Mental State Examination (MMSE) between
PCA and control groups (P , .0001), and between tAD and
control groups (P, .0001); however, no significant difference
was found between PCA and tAD groups (P5 .2 at baseline,
P5.3at follow-up).BothPCAand tADpatients showedasim-
ilar decline inMMSE frombaseline to follow-up (2.6 points in
PCA, 2.4 points in tAD, with similar,w1 year, intervals be-
tween time points). Furthermore, no significant differences
were found for total intracranial volume (TIV) (P5 .8 across
groups, P . .5 between groups). Whole brain volume at
baseline and follow-up, adjusted for TIV,was significantly dif-
ferent across groups (P, .0001 for both baseline and follow-
up) and between each patient group and the control group
(P, .001 for both PCA and tAD patients). No significant dif-
ferences in baseline and follow-up whole brain volume were
found between PCA and tAD patients (P 5 .7 at baseline,
P5 .8 at follow-up).
The most commonly reported initial symptoms (Table 2)
in the PCA group were difficulties with arithmetic (71%),
spelling (41%), and locating objects (41%). A high propor-
tion of PCA patients also reported difficulties with “mem-
ory” (47%), whereas a much lower proportion showed
impaired performance on memory tasks on formal neuro-
psychological testing at visit 1 (29%; Table 3). The most
commonly reported clinical feature on neurological exami-
nation in the PCA group was dyspraxia (47%), followed
by visual disorientation (24%). Neuropsychological testing
(Table 3) revealed that all PCA patients showed impaired
performance on the letter cancellation task (100%), and
the majority of PCA patients also showed visuospatial
(88% at visit 1) and visuoperceptual difficulties (82% at
visit 1). In the tAD group, besides impaired performance
on visual and verbal memory tasks (as defined by inclusion
criteria), patients showed difficulties with visuoperceptual
processing (81%) and arithmetic (81%). The PCA group
showed a decline in performance on all tests, with a particu-
larly marked drop in performance on the verbal memory
task. A decline in performance was also revealed in the
tAD group, except on visual memory, letter cancellation,
arithmetic, and visuoperceptual processing tests. Formal sta-
tistical testing (c2 test) of changes in performance between
visit 1 and visit 2 in each group did not reveal significant dif-
ferences. However, comparing performance at visit 1 be-
tween PCA and tAD patients revealed that the PCA group
performed significantly better on the verbal memory task
(P , .001) and arithmetic (P 5 .01), whereas performance
in the PCA group was significantly worse on tasks of visuo-
spatial processing (P 5 .01) and the letter cancellation task
(P 5 .02) compared with the tAD group.3.2. Boundary shift integral
Table 4 shows the means and standard deviations of the
annualized brain atrophy rates in control subjects, PCA pa-
tients, and tAD patients, as well as adjusted group differ-ences and P values of significance. BSI is reported in
milliliters as well as percentage of whole brain volume at
baseline. TIV was not significant when included as a covari-
ate in this model (P 5 .3 for milliliter BSI, and P 5 .7 for
percentage BSI). Atrophy rates were significantly different
between the patient groups and the control group (P ,
.0001 for both PCA and tAD patients) and across all groups
(P , .0001). The PCA group showed higher atrophy rates
compared with the tAD group; however, this difference
was not statistically significant (P 5 .08).
3.3. Longitudinal gray matter volume changes: control
group versus patient groups
Both the PCA and tAD groups showed ongoing global
changes in gray matter atrophy compared with the control
group (Fig. 1A, B for sagittal view of the right hemisphere,
Fig. 2A, B for coronal view, Fig. 3A, B for axial view; please
refer to Fig. S1A, B for sagittal view of the left hemisphere).
Both groups showed most significant atrophy changes in
temporal and parietal lobe regions, with some additional
gray matter atrophy changes in the frontal lobe.
3.4. Longitudinal gray matter volume changes: PCA
patients versus tAD patients
The direct comparison of longitudinal changes in gray
matter volume between PCA and tAD groups did not return
statistically significant results after FDR correction. Effect
size maps (as a Pearson correlation coefficient) for differ-
ences in gray matter volume change between these two
groups are shown in Fig. S2.
3.5. Classification analysis
The results of the classification analysis (accuracies, sen-
sitivities, and specificities) are presented in Table 5. Using
Fig. 1. Longitudinal changes in gray matter volume (sagittal view of the right hemisphere) in (A) posterior cortical atrophy (PCA) patients compared with
control subjects and (B) typical amnestic Alzheimer’s disease (tAD) patients compared with control subjects. (C) Maps show regions that were most influential
in making a classification between PCA and tAD groups. The color bar for the control comparisons (A and B) show t values for false discovery rate (FDR)-
corrected results (P, .05), with warmer colors indicating greater volume loss in PCA and tAD patients compared with control subjects. (C) Red represents areas
where relatively lower gray matter volume change indicates PCA, whereas blue shows areas where lower gray matter volume change indicates tAD. A, anterior;
P, posterior.
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fication accuracies of 97.1% for PCA patients and 94.1% for
tAD patients, against control subjects, were obtained. Sensi-
tivity was 94.1% (specificity 100%) for PCA group and
87.5% (specificity 100%) for tAD group. The direct classifi-
cation of PCA and tAD groups produced an accuracy of
72.7% (P , .01; 95% confidence interval [CI]: 54.5, 86.7),
which represents a reasonable classification accuracy, with
the confidence intervals indicating that it is significantly dif-
ferent from chance. Specificity for PCAwas 75.0% (95% CI:
47.6, 92.7), and sensitivity for tAD was 70.6% (95% CI:
44.0, 89.7).
Regions in which loss of gray matter contributed most to
the classification of PCA and tAD groups are presented in
Fig. 1C, Fig. 2C, and Fig. 3C. These patterns are very similar
to those found in the PCA versus tAD difference map
(Fig. S2). The classification map revealed that regions with
gray matter loss contributing most to a classification of
PCAwere the left medial temporal lobe, bilateral supramar-
ginal and inferior parietal lobe, head of the caudate nucleus,
and frontal lobe regions. In contrast, regions with atrophy
progression contributing most to a classification of tAD
were bilateral anterior, middle, and superior temporal loberegions; frontal lobe regions, including the frontal pole; pre-
cuneus; superior parietal lobe; and thalamus.4. Discussion
Patients with AD typically present with amnestic prob-
lems and medial temporal lobe atrophy but may less com-
monly also present with posterior deficits and posterior
cortical atrophy (PCA). This study investigated the progres-
sion of atrophy in PCA patients compared with tAD patients
and healthy control subjects. Compared with control sub-
jects, after a disease duration of 5 years, both PCA and
tAD patients showed widespread gray matter loss, including
changes in medial temporal and frontal lobe regions in the
PCA group and in posterior regions in the tAD group. Differ-
ences in atrophy progression between PCA and tAD patients
were subtle, reaching statistical significance only when us-
ing a multivariate classification approach.
Cross-sectional studies have shownmarked focal patterns
of atrophy in PCA and tAD patients [14,15], suggesting that
at some point during the disease atrophy changes are
relatively confined to posterior regions in PCA and to
medial temporal lobe regions in tAD. The widespread
Fig. 2. Longitudinal changes in gray matter volume (coronal view) in (A) PCA patients compared with control subjects and (B) tAD patients compared with
control subjects. (C) Maps show regions that were most influential in making a classification between PCA and tAD groups. The color bar for the control com-
parisons (A and B) show t values for FDR-corrected results (P,.05), with warmer colors indicating greater volume loss in PCA and tAD patients compared with
control subjects. (C) Red represents areas where relatively lower gray matter volume change indicates PCA, whereas blue shows areas where lower gray matter
volume change indicates tAD. L, left; R, right.
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compared with the control group may therefore suggest
that these initial focal patterns of atrophy changes become
more global as the diseases progress. This is in accordance
with previous reports showing that anterograde memory
functions, linguistic skills, and frontal lobe functions, which
are sometimes strikingly preserved in the earlier stages of
PCA, gradually deteriorate as patients progress to a more
global dementia state [10,51], making their presentation
ultimately indistinguishable from that found in advanced
tAD [52].
The classification analysis produced accuracies of 97%
and 94% for discriminating control subjects from PCA and
tAD patients, respectively. Accuracy for separating PCA
and tAD groups using the same multivariate classification
approach was lower (72.7%) but statistically significant.
To our knowledge, this is the first study to use a pattern
classification algorithm to discriminate between PCA and
tAD patients using longitudinal structural MRI data. Previ-
ous studies have used classification methods to classify
patients with AD, MCI, and frontotemporal dementia, using
cross-sectional volumetric and cortical thickness data.Classification accuracies reported for the discrimination be-
tween AD and control groups vary between 75% and 100%,
depending on measurement unit, classification method, and
subject definitions used [53–57]. Accuracies of 84% [54]
and 89% [55] have been reported for the discrimination of
AD from frontotemporal dementia, and 73% [56] and 82%
[58] for the discrimination between MCI-converters versus
nonconverters. Wilson et al used an SVM (with principal
component dimensionality reduction) to discriminate be-
tween different language variants (semantic dementia, pro-
gressive nonfluent aphasia, logopenic progressive aphasia)
and reported accuracies between 81% and 94% [50]. Leh-
mann et al reported 98% accuracy for separating PCA
patients from control subjects using an SVM and cross-
sectional cortical thickness data [59].
Although subject numbers in this study are relatively
high, given the rarity of PCA, our study may not have
been sufficiently powered to detect statistically significant
longitudinal differences between the PCA and tAD groups
using the mass-univariate VBM approach. However, the
global patterns of atrophy changes in PCA and tAD groups
compared with the control group point to a relatively global
Fig. 3. Longitudinal changes in gray matter volume (axial view) in (A) PCA patients compared with control subjects and (B) tAD patients compared with con-
trol subjects. (C) Maps show regions that were most influential in making a classification between PCA and tAD groups. The color bar for the control compar-
isons (A and B) show t values for FDR-corrected results (P, .05), with warmer colors indicating greater volume loss in PCA and tAD patients compared with
control subjects. (C) Red represents areas where relatively lower gray matter volume change indicates PCA, whereas blue shows areas where lower gray matter
volume change indicates tAD. L, left; R, right.
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the fact that differences between PCA and tAD patients were
sufficient to enable a multivariate classification approach to
achieve statistically significant group separation may en-
courage further studies that assess longitudinal structural
changes in larger subject groups. Taken together, our find-
ings support the hypothesis that although regions of greatest
total tissue loss in both groups remain those typically asso-
ciated with these diseases (i.e., posterior regions in PCA,
medial temporal lobe regions in tAD), both PCA and tAD
patients show global changes in gray matter loss at this stage
of the disease.Table 5
Classification accuracies, specificities, and sensitivities with 95% confidence inte
Groups Accuracy
Control subjects versus PCA patients 97.1 (85.1, 99.9)
Control subjects versus tAD patients 94.1 (80.3, 99.3)
PCA patients versus tAD patients 72.7 (54.5, 86.7)
Abbreviation: VBM, voxel-based morphometry.Whole brain atrophy rates, as measured using the BSI,
were approximately 5 times higher in PCA and tAD groups
than in the control group. Atrophy rates in the PCA group
were slightly higher than in the tAD group; however, the
age- and sex-adjusted difference of 0.2%/year was not statis-
tically significant. The mean rate of loss of 1.9%/year found
in the tAD group was comparable with losses found in
previous studies of approximately 1.6% to 2% per year
[17,42,60].
Studies including milder cases of PCA are required to
fully understand the evolution of PCA from the earliest
symptomatic stages. The recruitment of patients with milderrvals in percent for each group comparison for the VBM longitudinal data
Specificity Sensitivity
100.0 (81.5, 100.0) 94.1 (71.3, 99.9)
100.0 (81.5, 100.0) 87.5 (61.7, 98.5)
70.6 (44.0, 89.7) 75.0 (47.6, 92.7)
M. Lehmann et al. / Alzheimer’s & Dementia 8 (2012) 502–512510PCA who are closer to symptom onset is often difficult be-
cause early visual symptoms are often mistaken as being
ophthalmological rather than neurological. Although most
baseline images selected for both patient groups (77% for
PCA, 75% for tAD) were the first scan available for each
subject, the mean disease durations were already 5 years.
These durations are also comparable with those reported in
other imaging studies of PCA, for example, Mendez et al
[34] (PCA: 4.5 years, AD: 4.2 years), Whitwell et al [14]
(PCA: 4.0 years, AD: 4.7 years), Schott et al [61] (PCA:
3.8 years, AD: 4.4 years), and McMonagle et al [51]
(PCA: 4.5 years). It would also be interesting to study pro-
gression of atrophy over multiple time points. Larger group
studies will also permit more detailed assessment of the var-
iance within the wider PCA population and, in particular,
whether a small number of individuals retain a truly focal
pattern of atrophy until late in the disease.
The cognitive and clinical features of the PCA patients in-
cluded in this study are consistent with those typically re-
ported in PCA studies [7,8,14,34,35]. A large proportion
of PCA subjects showed visuospatial and visuoperceptual
deficits, as well as dyscalculia, dysgraphia, dyspraxia, and
visual disorientation. A number of patients also reported
difficulties with their memory as an initial symptom. It
should be noted, however, that these subjective memory
complaints may not necessarily reflect difficulties with
episodic memory per se, but rather may indicate other
nonamnestic cognitive symptoms that are difficult for the
patient to articulate [62]. This may explain the relatively
smaller proportion of individuals with PCAwho showed im-
paired memory performance on formal neuropsychological
testing 5 years after symptom onset.
Because the current study aimed to investigate patterns of
atrophy changes using MR images, we wished to maximize
the number of subjects with comparable image acquisition
(i.e., type of scanner and scan interval). For that reason, in-
dividuals were drawn from different research studies, which
used different neuropsychological assessments. As a result,
the psychometric testing data did not permit a more detailed
assessment of cognitive progression in these subjects. Fur-
ther studies that include detailed longitudinal neuropsycho-
logical assessments are needed to investigate the progression
of cognitive deficits over time in these patients. It would fur-
ther be interesting to investigate the clinical correlates of the
involvement of specific regions in PCA and tAD patients,
such as the hippocampus, thalamus, and caudate. In this
study, performance on a speed test (letter cancellation),
which might represent a neuropsychological correlate for
atrophy of subcortical structures such as the thalamus and
caudate, was impaired in the majority of PCA patients. How-
ever, deficits on this test are also likely to be driven by visual
disorientation and visuospatial impairment, potentially mak-
ing performance on this task less informative in PCA pa-
tients. Tests that assess the cognitive processes associated
with these subcortical structures and that are less affected
by visual dysfunction need to be considered in future studies.Furthermore, because differences in gray matter volume los-
ses between PCA and tAD patients were very small, inter-
pretations of the involvement of these regions should be
made with caution.
Although studies have shown that AD is the underlying
pathology in the majority of PCA patients [10,11], the
syndrome may be attributable to non-AD pathologies in
a small number of patients. In this study, pathological confir-
mation was only available in one PCA patient (AD with ad-
ditional Lewy body pathology) and four tAD patients (all
AD pathology).
In conclusion, this longitudinal study shows that although
PCA and tAD patients retain their regional predilection, with
PCA continuing to showmarked atrophy in posterior regions
and tAD in the medial temporal lobe, as the diseases prog-
ress, other areas become involved as well, resulting in an in-
creasingly widespread pattern of atrophy progression in both
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